GLOBAL PERSPECTIVES ON PRECISION MANAGEMENT OF MENOPAUSAL SYNDROMEGulzodaNegmatovaauthorCharosBaxronovaauthorFatimaIskandarovaauthorMenopausal syndrome, characterized by vasomotor symptoms (VMS), psychological disturbances, and genitourinary syndrome of menopause (GSM), affects over 1.2 billion women worldwide, with profound implications for quality of life and long-term health outcomes. This thesis synthesizes advancements in diagnostics and management from 2017–2025, focusing on biomarker panels (e.g., follicle-stimulating hormone [FSH], anti-Müllerian hormone [AMH]), artificial intelligence (AI)-driven symptom profiling, and novel therapeutics, including neurokinin 3 receptor (NK3R) antagonists (e.g., fezolinetant) and bioidentical hormone therapy. Precision medicine approaches, integrating genetic (e.g., CYP2D6 polymorphisms), microbiome, and lifestyle data, achieve up to 90% symptom reduction in tailored interventions. The thesis addresses global health disparities, with only 10% of women in low- and middle-income countries (LMICs) accessing treatment, and proposes equitable solutions like low-cost diagnostics and telemedicine. Clinical studies (n=120) demonstrate that non-hormonal therapies reduce VMS by 50–70%, while AI tools predict symptom severity with 85% accuracy. Challenges include underdiagnosis (60% in LMICs), cultural stigma, and limited access to advanced therapies. Future directions emphasize AI-based predictive models, microbiome modulation, and scalable health interventions to ensure universal access by 2030. This work aims to inform clinical practice and guide research toward equitable, personalized menopausal care.2025-06-14Maqola